Cipla Stays Upbeat On Advair Generic With ‘Superior’ Cost Position, Derisks Abraxane

Outlines Impact Of China Zero-COVID Policy

Generic Revlimid, lanreotide propel Cipla’s US business to a high in the fiscal second quarter, with products like leuprolide depot set for debut ‘any time now’. Management signals cost edge for generic Advair as it awaits further word following a FDA establishment inspection report at its Indian site, while a Plan B is being initiated for generic Abraxane.

New Revenue Base For Cipla's US business • Source: Shutterstock

Cipla Limited signaled a new revenue base for its US business in the fiscal second quarter, buoyed by the ongoing market share expansion of its partnered peptide asset lanreotide and the launch of generic Revlimid (lenalidomide).

Cipla’s 505(b)(2) hybrid lanreotide injection product has seen market share move up to 9.6% in the second quarter, from 4.6%...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip